- Net revenue reached $37.8 million (+45% YoY), driven by $34.0 million from MIPLYFFA.
- Net income turned positive to $19.2 million ($0.26 diluted EPS) vs. $(0.5) million loss in Q3 2025.
- Cash position stood at $270.9 million at end of period.
Signal #119338 · SEC 8-K
$ZVRA SEC Filing Alert & Real-Time AI Stock Impact Analysis
Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).
FAQ: $ZVRA filing catalyst
Why did $ZVRA trigger an AI stock catalyst alert?
$ZVRA triggered a Stock Catalyst AI alert on 2026-11-03 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.8/10). Headline: Zevra Therapeutics Reports Q3 Net Revenue of $37.8M (+45% YoY), Net Income of $19.2M. Key points: - Net revenue reached $37.8 million (+45% YoY), driven by $34.0 million from MIPLYFFA. - Net income turned positive to $19.2 million ($0.26 diluted EPS) vs. $(0.5) million loss in Q3 2025. - Cash position stood at $270.9 million at end of period.
How did $ZVRA stock react after the SEC filing?
After the SEC 8-K for $ZVRA, observed market reaction: T0 price $10.26. Past moves do not guarantee future results.
Where can I get real-time $ZVRA SEC filing alerts?
Stock Catalyst AI pushes real-time SEC 8-K alerts for $ZVRA via Telegram and the VIP Web Terminal from €10/month.